



# **Epstein-Bar Virus Infection**

## SHIVA SAMAVAT Associate Professor of Nephrology Shahid Labbafinejad Medical Center; SBMU








• Epstein–Barr virus (EBV) is a human herpesvirus 4 (HHV-4)

• EBV is a ubiquitous viral pathogen, with a seroprevalence of more than 90% in adults.

• Most primary EBV infections occur during childhood and are asymptomatic.


Infectious mononucleosis






## **Clinical Syndromes**


Non-neoplastic EBV infections EBV-associated hemophagocytic lymphohistiocytosis




Systemic EBV infections


Chronic active EBV infection














# Pathogenesis of EBV Infection





















B cell transformation PTLD B cell B cell **操** Anti-viral therapy PDL1 PXXXXXXX XXXXX CD20 EBV Introduction of T cells EBV-specific immunosuppression TCR NKG2D Cytotoxic granule PD-1 NK CD4 CD4 PD-1 CD8 CD8




NK



- •Lack of cytotoxic T cell response
- CD4+ T cell lymphopenia
- Increased exhausted CD8<sup>+</sup> T cells (PD<sub>1</sub><sup>+</sup> CD<sub>8</sub><sup>+</sup> T cells)
- Viral replication
- •B cell Transformation


• Eventually lead to PTLD





# Risk factors of EBV infection






- •EBV sero-mismatch
- Overimmunosuppression:
  - ATG: ATG should be used with caution in EBV D+/R- patients.
  - EBV replication more often in patients receiving belatacept, than it does in those receiving cyclosporine.
  - MMF maintenance has a role in preventing EBV DNAemia.



American Journal of Transplantation 2013; 13: 656–562

Experimental and Clinical Transplantation (2014) 3: 212-219





## **Evaluation and Management of Candidates** for Kidney Transplantation


10.5.5 Epstein-Barr virus (EBV) 10.5.5.1: We recommend screening for EBV with EBV viral capsid antigen

(VCA) IgG and/or EBV nuclear antigen (EBNA) IgG (1C).

(v))

April 2020 Volume 104 Number 4S






#### Recommendations for initial and follow-up screening of viral and non-viral pathogens in kidney transplant candidates.

Pathogen	Test	Repeat testing
Viral infections		
HIV	lgG	If negative, repeat annually and at time of transplant
HCV	lgG	If negative, repeat annually and at time of transplant
HBV	Anti-HBs, Anti-HBc, HBsAg	If negative, repeat annually and at time of transplant
CMV	lgG	If negative, repeat at time of transplant
EBV	VCA IgG or EBNA IgG	If negative, repeat at time of transplant
HSV	lgG	If negative, repeat at time of transplant
VZV	IgG	If negative, repeat at time of transplant and 4 weeks post-vaccination
Measles, Mumps, Rubella	lgG	If negative, repeat at time of transplant and 4 weeks post-vaccination
HTLV	IgG	None unless ongoing risk of exposure
Non-Viral infections		
Syphilis	IgG with confirmatory testing if IgG positive	None
Strongyloides	lgG	None
Chagas disease	IgG	None
Tuberculosis	Tuberculin skin test or Interferon-gamma	Annually if ongoing risk of exposure
(in low prevalence areas)	release assay (IGRA)	
Malaria	Blood smear if clinically indicated	None

### April 2020 Volume 104 Number 4S






### 13.3: EPSTEIN-BARR VIRUS AND POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE

- 13.3.1: We suggest monitoring high-risk (donor EBV seropositive/recipient seronegative) KTRs for EBV by NAT (2C):
  - once in the first week after transplantation (2D);
  - then at least monthly for the first 3–6 months after transplantation (2D);
  - then every 3 months until the end of the first post-transplant year (2D); and
  - additionally after treatment for acute rejection. (2D)








Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

Upton D. Allen<sup>1,2,3</sup> | Jutta K. Preiksaitis<sup>4</sup> | on behalf of the AST Infectious Diseases Community of Practice






2. We recommend EBV viral load surveillance and preemptive interventions in patients who are EBV-seronegative pre-transplant (*weak/low*). In patients who receive seropositive donor organs, monitoring should occur weekly to biweekly, when possible over the first post-transplant year until EBV DNAemia is detected. When this occurs, monitoring should occur weekly during initial acute phase of infection, then less frequently by increasing increments until "set point" is achieved (weak/

Clinical and Translational Research








very low). Less frequent initial monitoring (monthly) for community-acquired infection should be considered in seronegative patients who receive seronegative donor organs. Ongoing monitoring beyond the first post-transplant year may be considered in patients who have fluctuating immunosuppression, rejection episodes or have not established a viral "set point."






3. Viral load surveillance and preemptive strategies are not routinely recommended for SOT patients who are EBV seropositive pre-transplant (adults: *strong/low*, children: *weak/low*) with the exception of intestinal transplant recipients (*weak/low*) and in situations where retransplantation occurs following PTLD (*weak/low*).

Journal of Clinical and Translational Research




### How to monitor?



• Whole blood or lymphocyte EBV viral load is higher and becomes detectable earlier than contemporaneously tested plasma.

• Patients should be monitored using the same sample type and the same assay in a single laboratory.






# • There are very few natural history studies relating EBV DNAemia levels to PTLD events.

•No specific cut-off.






• More useful than a single value might be the trend in viral loads. (rapidly rising count)

 Most centers are more likely to intervene by reducing immunosuppression when loads are serially increasing.






- •Adjunctive laboratory testing may improve the specificity of high viral load as a predictor of PTLD:
  - •EBV-specific T-cell ELISPOT assays
  - Virus-specific T cell by cytokine flow cytometry
  - CD20 or CD4/CD8/NK cell counts




### Virus-specific T cells



• There is increasing evidence that virusspecific T cells mirror not only the virusspecific but also the general cellular immune defense.

• They may serve as an indicator of the intensity of immunosuppression as well as a prognostic marker for virus-induced diseases after transplantation.






• High levels of EBV-specific CD4 T cells are associated with asymptomatic self-limiting EBV viremia, whereas lack or low levels of EBV-specific CD4 T cells are found in the case of symptomatic, long-term viremia.

• They might be additionally used for steering of the intensity of IS treatment to avoid overimmunosuppression





### Steering of Tx-Immunosuppression by Virus-Specific T Cells (IVIST-Trial)




### Conclusion

Additional steering of immunosuppressive therapy by Tvis levels is safe, results in a similar GFR and personalizes immunosuppressive therapy by lowering exposure to immunosuppressive drugs leading to economic benefits.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY





doi: 10.1681/ASN.2020050645

## Current approaches for EBV(D+/R-) KTR

- Antiviral drugs (universal prophylaxis)
- •IVIG (universal prophylaxis)
- •Monitoring for EBV load by PCR (preemptive prophylaxis):
  - Adjustment of immunosuppression,
  - Antiviral drugs
  - IVIG
  - Infusion of EBV-specific cytotoxic T cells
  - Monoclonal antibody: CD20+ B cells



### The Role of Antiviral Prophylaxis for the Prevention of Epstein– Barr Virus–Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review





Figure 4: Effect of antiviral prophylaxis on the incidence of PTLD by subgroups of antivirals given for preempt only and prophylaxis only. CI, confidence interval; M-H, Mantel-Haenszel; PTLD, posttransplant lymphoproliferative disease.

American Journal of Transplantation 2017; 17: 770–781

t))erapy

### Bal all 1. **B** cell transformation B cell 花 Anti-viral therapy 恭恭 PXXXXXXXX xxxx EBV T cells EBV-specific TCR NKG2D Cytotoxic granule PD-1 NK CD4 PD-1 CD8





**Recommendations: prevention** 

1. The use of antiviral agents, IVIG, and adoptive immunotherapy as universal prophylaxis for early PTLD prevention in EBV-mismatched patients is not recommended (*weak/low*).



# TRANSPLANT INFECTIOUS DISEASE

**Original Article** 

Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study

Thomas Schachtner 💌, Petra Reinke

First published: 15 September 2016 | https://doi.org/10.1111/tid.12605 | Citations: 16

Prophylactic rituximab given prior to transplantation appears to reduce EBV transmission, EBV viremia, and associated development of PTLD in EBV(D+R–) living KTRs.




Letter To The Editors

Multitarget anti-EBV therapy to prevent primary infection in kidney transplant recipients from deceased donor, at risk of post-transplantation lymphoproliferative disorder (EBV D+/R–)

Simon Ville 🔀, Jacques Dantal


First published: 17 May 2020 | https://doi.org/10.1111/tri.13652

- 4 KTRs from deceased donors.
- A single dose of rituximab (375 mg/m2 IV, day 0 post-transplantation),
- anti-viral drugs (valganciclovir 450 mg twice daily, 6 months) and IVIG (0,4 g/kg on day 0 and 1).
- Patients received basiliximab as induction therapy, and tacrolimus (though level between 6 and 8 ng/L) combined with acid mycophenolic (720 mg twice a day).
- At the last follow-up ranging from 24 to 36 months, no one has developed PTLD.



# Posttransplant Lymphoproliferative Disease






• The overall 5-year PTLD rates in adults ranged from 0.6 to 9%, with a higher rate for intestinal and lung transplantations, but also for seronegative recipients.

• With highest risk in the first year posttransplant but remaining increased beyond 10 years.





#### Variable

#### **Risk after Solid-Organ Transplantation**


Established risk factors

Type of transplanted organ, relative risk: multiorgan and intestinal, 239.5; lung, 58.6; pancreas, 34.9; liver, 29.9; heart, 27.6; kidney, 12.6

EBV mismatch at time of transplantation (recipient EBVnegative, donor EBV-positive); relative risk, 10–75

Intensity of induction immunosuppressive therapy and duration of maintenance therapy (including graftrejection episodes); overall SIR, 10






#### Strong evidence of risk

Increased risk associated with ATG, OKT3, tacrolimus, azathioprine, new agents (e.g., belatacept in EBVnegative transplant recipient)

Controversial degree of risk associated with alemtuzumab, cyclosporine, mTOR inhibitors

No increase in risk associated with mycophenolate mofetil, basiliximab, daclizumab





#### Weak evidence of risk

Underlying disorder (HCV, cystic fibrosis, autoimmune hepatitis)

Race or ethnic group (risk in descending order): white, black, African

Monoclonal gammopathy of undetermined significance (in recipient)


Non-EBV infection (HCV or CMV infection)

Older donor age and younger recipient age

Cytokine gene polymorphisms

HLA alleles, haplotypes, mismatches, antibodies

### **Clinical Manifestations**



 Nonspecific (fever, weight loss, allograft dysfunction, anemia)

• Reflect the site of localization of the mass (lymph node enlargement across one or several different sites externally or internally, symptoms referable to gastrointestinal tract, brain, liver, or kidney).



# A rare presentation of a posttransplant lymphoproliferative disorder






Figure 1 | Cutaneous plasmacytoma overlying the left shin showing extensive violaceous nodules, some of which have coalesced to form a single mass.

Kidney International (2018) 93, 761; https://doi.org/10.1016/j.kint.2017.10.013


#### Early vs late-onset PTLD



• Early-onset PTLD tends to be EBV-driven and often involves the allograft, younger age, extranodal disease, prior treatment of acute rejection, B-cell lymphoma histology, and tumor EBV positivity.

• Burkitt lymphoma and Hodgkin disease were observed only in late PTLDs, which are more likely to present with nodal disease.







• Although there is a decrease in the risk of early PTLD, the risk of late PTLD is prolonged, possibly as a result of improved survival of KTRs.


• This is consistent with the fact that higher recipient age is associated with late-onset PTLD.



### Pathogenesis








### **Classification of PTLD by WHO**

Characteristic	Nondestructive PTLD†	Polymorphic PTLD	Monomorphic PTLD	Hodgkin's Lymphoma–like PTLD
Underlying architecture	Nondestructive	Destructive	Destructive	Destructive
Composition	Plasma cells, small lympho- cytes, immunoblasts	Complete spectrum of B-cell maturation	Fulfills specific WHO criteria for NHL; mantle-cell and follicular NHL are not considered PTLD	Fulfills specific criteria for classic Hodgkin's lymphoma
Immunohistochemical features	No diagnostic value	Mixture of B cells and T cells	Monoclonal population 90% DLBCL, mostly CD20+ (majority ABC type)	CD20-, CD30+; most cases CD15+
EBV association	Almost 100%	>90%	Both EBV-positive and EBV-negative	>90%
Clonality	No in most cases	Variable	Yes	Yes
Molecular genetic findings	None	Variable (BCL6 somatic hypermutations)	Differences between EBV-positive (genomic stable) and EBV-negative (similar to DLBCL in immunocompetent patients)	No information available
Clinical features	Mostly early PTLD	Variable	Both early and late PTLD	Possible increase in incidence of late- onset Hodgkin's lymphoma after allogeneic HSCT

\* Information is from Swerdlow et al.<sup>26,27</sup> ABC denotes activated B-cell, DLBCL diffuse large B-cell lymphoma, NHL non-Hodgkin's lymphoma, and WHO World Health Organization. † Nondestructive PTLD includes plasmacytic hyperplasia PTLD, infectious mononucleosis–like PTLD, and florid follicular hyperplasia PTLD.




### **Non-EBV-related tests**



- •Lymphopenia
- •Anemia
- Disturbed serum electrolytes, liver, and renal function tests.
- •Elevations in serum uric acid and LDH
- •The presence of concomitant CMV infection should be determined
- Serum IL-6, serum/plasma-free light chains, serum sCD30, serum CXCL13,




#### **EBV-related tests**




- Anti-VCA IgG and anti-EBNA-1 IgG are serologic tests
- Whole blood or lymphocyte EBV viral load is higher and becomes detectable earlier than contemporaneously tested plasma samples.
- EBV-specific T-cell ELISPOT and tetramer assays, these assays may be more useful for disease occurring early after transplantation.






#### Treatment



Treatment	Mechanism of Action	Indications	Considerations
Reduction of immunosuppression	Restoration of T-cell function — in particular, EBV-specific T-cell response	Preemptive therapy in high-risk transplantations; first-line treatment for all PTLD subtypes	High response rates for nondestructive PTLD; responses also observed in EBV-negative cases; takes time, which may not be feasible in very aggressive cases; not indicated as sole up- front therapy for monomorphic non-DLBCL subtypes; risk of organ rejection (can be performed more aggressively with kidney and pancreatic transplants than with other transplant types); less effective after allogeneic HSCT than after SOT
Surgery	Reduction of tumoral mass	Limited stage of disease; palliative care	Combined with reduction of immunosuppression; rapid symp- tom relief
Radiotherapy	Reduction of tumoral mass	Limited stage of disease; after chemotherapy in HL; whole-brain radiotherapy in PCNSL if che- motherapy contraindicated; palliative care	Combined with reduction of immunosuppression; rapid symp- tom relief
Chemotherapy	Reduction of tumoral mass	For nondestructive PTLD, polymorphic PTLD, or monomorphic DLBCL in patients who do not have complete remission after reduction of im- munosuppression plus rituximab; lymphoma- specific therapy for other (non-DLBCL) mono- morphic subtypes	High response rates; risk of infection; reduced treatment-related morbidity and mortality over past two decades
Rituximab	Reduction of tumoral mass	First-line treatment (after reduction of immuno- suppression) for nondestructive PTLD, poly- morphic PTLD, or monomorphic DLBCL; com- bined with chemotherapy in all non-DLBCL, CD20+ monomorphic subtypes; role in pre- emptive therapy	Only for CD20+ PTLD; favorable toxic-effects profile; improves performance status before chemotherapy; risk of infection




### **Reduction in Immunosuppression**




- Reducing CNI dose (targeting 30- 50% reduction of trough levels),
- Discontinuing antimetabolites (AZA, MMF)
- •Continuing steroids if possible.
- •The time period one should wait before proceeding to alternative therapeutic interventions: within 2-4 weeks?!






• Bulky disease (largest tumor deposit, >7 cm in diameter), an advanced stage (Ann Arbor stage III or IV), and older age (>50 years) are independently associated with a lack of response to reduced immunosuppression.





• A case series report described conversion to mTORi (everolimus or sirolimus) and subsequent minimisation or withdrawal of calcineurin inhibitors in 19 renal transplant recipients with PTLD; remission was achieved in 15 patients.






• The use of rituximab as the next step in the treatment of most CD20+ B-cell PTLD when RIS does not result in complete remission.

•4 administrations of rituximab






Treatment	Mechanism of Action	Indications	Considerations
Treatment	Mechanism of Action	indications	Considerations
Adoptive immunotherapy (EBV-specific cytotoxic T-cells)	Restoration of EBV-specific T-cell response	Relapsed or refractory PTLD; possible preemptive therapy	Only for EBV-positive cases; time-consuming, high costs, and limited availability; low toxic-effects profile (no risk of GVHD, in contrast to classic donor lymphocyte infusions)
Antiviral therapy	Targeting of EBV	Promising role in combination with viral thymidine kinase–inducing agents (e.g., the HDAC inhibi- tor arginine butyrate), but not further devel- oped	No efficacy as monotherapy (absence of viral thymidine kinase expression in EBV-positive PTLD); only for EBV-positive cas- es
High-dose therapy and autologous HSCT	Reduction of tumoral mass	Relapsed or refractory PTLD	Feasible, but limited experience

\* HDAC denotes histone deacetylase, HL Hodgkin's lymphoma, PCNSL primary central nervous system lymphoma, and SOT solid-organ transplantation.




### **EBV-specific CTLs**



### •EBV-specific CTLs;

- autologous (solid organ transplantation)
- donor- derived allogeneic (hematopoietic stem cell transplantation)
- the use of partially HLA- matched EBV-specific CTLs from healthy donors





#### **ORIGINAL ARTICLE**

#### WILEY

#### Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children

No.	Age	Primary disease	Graft, age at transplant	Site of PTLD	WHO classification	Prior treatment	No. of EBV-CTL infusions	HLA match between recipient and donor CTL <sup>a</sup>	Response to EBV-CTL
1	11 y	Alpha-1 antitrypsin deficiency	Liver, 2 y	LN	Hodgkin's disease	RIS, IG, antiviral	4	3 of 6	NR
2	4 y	BA	Liver, 10 mo	LN, GI, liver	Polymorphic	RIS, antiviral	2	3 of 6	CR
3	17 mo	Hirschsprung disease	Liver+SB, 9 mo	LN, GI	Monomorphic	RIS, IG, antiviral	1	2 of 6	CR
4	2 y	Congenital intestinal pseudo-obstruction	Liver+SB, 11 mo	GI	Monomorphic	RIS	4	3 of 6	CR
5	12 y	CF-related liver disease	Liver, 11 y	LN, GI, liver	Monomorphic	RIS, antiviral	4	3 of 6	CR
6	12 mo	BA	Liver, 9 mo	LN, GI, tonsil	Monomorphic	RIS, antiviral	4	5 of 6	CR
7	14 mo	BA	Liver, 11 mo	GI	Monomorphic	RIS, rituximab	4	5 of 10	CR
8	4 y	ARPKD and polycystic liver disease	Liver+kidney, 4 y	LN	Monomorphic	RIS, rituximab, IG	4	5 of 10	CR
9	6 y	Malrotation, volvulus	Liver+SB, 2 y	GI	Polymorphic	RIS, rituximab	4	7 of 10	PR
10	21 mo	NEC	Liver+SB, 1 y	GI	Monomorphic	RIS	4	3 of 6	NR



Pediatric Transplantation. 2018;e13133.

## The Journal of Clinical Investigation


Off-the-shelf EBV-specific T cell immunotherapy for rituximabrefractory EBV-associated lymphoma following transplantation

Susan Prockop, ..., Aisha Hasan, Richard J. O'Reilly

J Clin Invest. 2020;130(2):733-747. https://doi.org/10.1172/JCI121127.

**METHODS.** We developed a third-party, allogeneic, off-the-shelf bank of 330 GMP-grade EBV-CTL lines from specifically consented healthy HCT donors. We treated 46 recipients of HCT (n = 33) or SOT (n = 13) with established EBV-PTLD, who had failed rituximab therapy, with third-party EBV-CTLs. Treatment cycles consisted of 3 weekly infusions of EBV-CTLs and 3 weeks of observation.


**RESULTS.** EBV-CTLs did not induce significant toxicities. One patient developed grade I skin graft-versus-host disease. Complete remission (CR) or sustained partial remission (PR) was achieved in 68% of HCT recipients and 54% of SOT recipients. For patients who achieved CR/PR or stable disease after cycle 1, one year overall survival was 88.9% and 81.8%, respectively. In addition, 3 of 5 recipients with POD after a first cycle who received EBV-CTLs from a different donor achieved CR or durable PR (60%) and survived longer than 1 year. Maximal responses were achieved after a median of 2 cycles.



ALLELE study: A multicenter, open label, phase III study of tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-driven posttransplant lymphoproliferative disease (EBV+ PTLD) after failure of rituximab or rituximab and chemotherapy

Tabelecleucel is an off-the-shelf, allogeneic EBV-specific T cell therapy.






### Other Therapies???


Table 4. Future Strategies for the Treatment of PTLD.\*

Treatment	Compound	Considerations
BTK inhibition <sup>78</sup>	Ibrutinib	May also be active in GVHD and graft rejection; promising activity in ABC-type DLBCL
Inhibition of PI3K and mTOR <sup>79</sup>	Idelalisib (PI3K inhibitor); sirolimus (rapamycin) and everolimus (mTOR inhibitors)	Strong in vitro evidence of involved pathways; mTOR inhibitors also have strong immunosuppressive activity, but their use in treatment of PTLD is controversial
Proteasome inhibition <sup>80</sup>	Bortezomib	In particular, may be useful for early PTLD after allogeneic HSCT
Radioimmunotherapy <sup>81</sup>	<sup>90</sup> Y-ibritumomab, tiuxetan	Effective in small pilot trial (SOT)
Checkpoint inhibitors <sup>82</sup>	Pembrolizumab, nivolumab	CTLA-4 pathway: contraindication, given high risk of (fatal) acute rejection; PD1 or PDL1 pathway: lower risk of acute rejection; should currently be considered only in clinical trials
Anti-CD30 therapy <sup>83</sup>	Brentuximab vedotin	Expression of CD30 in 85% of all PTLD subtypes; responses de- scribed in case reports

\* BTK denotes Bruton's tyrosine kinase, CTLA-4 cytotoxic T-lymphocyte–associated antigen 4, PD1 programmed death PDL1 programmed death ligand 1, and PI3K phosphoinositide 3-kinase.








During treatment of PTLD using strategies other than RIS, infection prophylaxis should be reviewed; prophylaxis for *Pneumocystis jirovecii* pneumonia should be reinstituted if it has been discontinued (*strong/high*).


The routine use of EBV viral load monitoring in peripheral blood to monitor treatment response to EBV + PTLD is not recommended (*weak/very low*).





# **Transplantation After PTLD**






• Recurrence of PTLD in patients having undergone retransplantation as a rare event.

• The ideal time gap between PTLD remission and listing for re-transplantation is not clear.






• The British Transplantation Society guidelines recommend a period of at least 1 year from the control of PTLD to retransplantation to minimize the risk of PTLD recurrence

 In the French registry, the median time from PTLD to listing for retransplantation was 65 months and from PTLD to retransplantation was 90 months






• EBV status at the time of retransplantation is an important predictor of recurrence after retransplantation.


 Patients should present an EBV seroconversion (an EBV IgG seropositive status) before retransplantation and it is advisable that EBV viral load be undetectable at the time of retransplantation.






- Patients with low level EBV viremia at the time of retransplantation may benefit from antivirals with intermittent measurements of EBV viral load and subsequent IS adjustments as per the viral load.
- Rituximab has also been used to prevent EBV viremia in EBV seronegative kidney transplant recipients.






 Rituximab has been used in retransplantations after PTLD both as a desensitisation protocol in high risk sensitised cases and as a prophylaxis for proliferation of EBV in cases with high viral counts





- IL-2R antagonists are the favoured induction agents.
- There is a trend to avoid induction with ATG preparations.
- Maintenance immunosuppression is generally the standard combination of CNI or, MMF and prednisolone
- Low target level





 Mycophenolate sodium is the only agent seen to have a significant protective effect against PTLD and its use is common in most series.

•mTOR inhibitors deserve a special mention in cases of PTLD?



